BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 14744796)

  • 1. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.
    Mizokami A; Koh E; Fujita H; Maeda Y; Egawa M; Koshida K; Honma S; Keller ET; Namiki M
    Cancer Res; 2004 Jan; 64(2):765-71. PubMed ID: 14744796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.
    Miyamoto H; Yeh S; Lardy H; Messing E; Chang C
    Proc Natl Acad Sci U S A; 1998 Sep; 95(19):11083-8. PubMed ID: 9736693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells.
    Chang HC; Miyamoto H; Marwah P; Lardy H; Yeh S; Huang KE; Chang C
    Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11173-7. PubMed ID: 10500149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
    Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Pharmacol; 1998 May; 55(9):1427-33. PubMed ID: 10076535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells.
    Harada S; Keller ET; Fujimoto N; Koshida K; Namiki M; Matsumoto T; Mizokami A
    Prostate; 2001 Mar; 46(4):319-26. PubMed ID: 11241555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.
    Zhao XY; Boyle B; Krishnan AV; Navone NM; Peehl DM; Feldman D
    J Urol; 1999 Dec; 162(6):2192-9. PubMed ID: 10569618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor.
    Heisler LE; Evangelou A; Lew AM; Trachtenberg J; Elsholtz HP; Brown TJ
    Mol Cell Endocrinol; 1997 Jan; 126(1):59-73. PubMed ID: 9027364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
    Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy.
    Culig Z; Klocker H; Bartsch G; Hobisch A
    Am J Pharmacogenomics; 2001; 1(4):241-9. PubMed ID: 12083956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
    Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
    Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
    Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
    Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
    J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.